company background image
BIM logo

bioMérieux Informe acción ENXTPA:BIM

Último precio

€98.70

Capitalización de mercado

€11.6b

7D

0.4%

1Y

0.08%

Actualizada

24 Nov, 2024

Datos

Finanzas de la empresa +

bioMérieux S.A.

Informe acción ENXTPA:BIM

Capitalización de mercado: €11.6b

Resumen de acción BIM

bioMérieux S.A. desarrolla y comercializa soluciones de diagnóstico in vitro para el diagnóstico de enfermedades infecciosas en América, Europa, Oriente Medio, África y Asia-Pacífico. Saber más

Análisis fundamental de BIM
Puntuación del snowflake
Valoración4/6
Crecimiento futuro3/6
Rendimiento pasado4/6
Salud financiera6/6
Dividendos0/6

Recompensas

Análisis de riesgos

No se han detectado riesgos en BIM a partir de nuestros controles de riesgos.

Competidores de bioMérieux S.A.

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de bioMérieux
Precios históricos de las acciones
Precio actual de la acción€98.70
Máximo en las últimas 52 semanas€111.50
Mínimo de 52 semanas€88.25
Beta0.22
1Cambio en 1 mes-5.91%
Variación en 3 meses-4.64%
Cambio de 1 año0.081%
3Variación en 3 años-24.34%
Variación en 5 años20.29%
Variación desde la OPV887.00%

Noticias y actualizaciones recientes

Recent updates

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Nov 01
Is bioMérieux (EPA:BIM) Using Too Much Debt?

Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?

Oct 14
Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?

bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing

Sep 26
bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing

bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

Sep 08
bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

Return Trends At bioMérieux (EPA:BIM) Aren't Appealing

Aug 03
Return Trends At bioMérieux (EPA:BIM) Aren't Appealing

bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

May 30
bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)

Apr 18
Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)

bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings

Mar 31
bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings

bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models

Mar 17
bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Mar 15
These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

Jan 27
bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward

Jan 06
bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward

A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Dec 16
A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Oct 23
These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger

Oct 05
bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger

There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings

Sep 15
There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings

Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Sep 07
Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Jun 30
Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down

Jun 09
Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Mar 31
Is bioMérieux (EPA:BIM) Using Too Much Debt?

The Return Trends At bioMérieux (EPA:BIM) Look Promising

Feb 23
The Return Trends At bioMérieux (EPA:BIM) Look Promising

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

Jan 27
Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet

Dec 16
bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet

bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth

Oct 18
bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Sep 14
Is bioMérieux (EPA:BIM) Using Too Much Debt?

Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital

Aug 11
Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital

An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued

Jul 23
An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

Jul 05
Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

May 26
bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns

May 11
Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns

bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year

Apr 23
bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year

bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85

Apr 09
bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

Mar 25
bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Mar 13
Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease

Feb 08
I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease

Why We Like The Returns At bioMérieux (EPA:BIM)

Dec 21
Why We Like The Returns At bioMérieux (EPA:BIM)

Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Dec 07
Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching

Nov 07
Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching

Is bioMérieux (EPA:BIM) A Risky Investment?

Oct 07
Is bioMérieux (EPA:BIM) A Risky Investment?

Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital

Sep 22
Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital

Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)

Sep 07
Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)

Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

Aug 06
Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital

Jun 15
There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital

A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)

May 31
A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)

Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

Apr 30
Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

bioMérieux (EPA:BIM) Could Easily Take On More Debt

Mar 28
bioMérieux (EPA:BIM) Could Easily Take On More Debt

The Trend Of High Returns At bioMérieux (EPA:BIM) Has Us Very Interested

Mar 13
The Trend Of High Returns At bioMérieux (EPA:BIM) Has Us Very Interested

Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Feb 25
Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

If You Had Bought bioMérieux (EPA:BIM) Shares Five Years Ago You'd Have Earned 237% Returns

Feb 09
If You Had Bought bioMérieux (EPA:BIM) Shares Five Years Ago You'd Have Earned 237% Returns

If You Like EPS Growth Then Check Out bioMérieux (EPA:BIM) Before It's Too Late

Jan 20
If You Like EPS Growth Then Check Out bioMérieux (EPA:BIM) Before It's Too Late

Could The Market Be Wrong About bioMérieux S.A. (EPA:BIM) Given Its Attractive Financial Prospects?

Dec 30
Could The Market Be Wrong About bioMérieux S.A. (EPA:BIM) Given Its Attractive Financial Prospects?

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Dec 17
These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Rentabilidad de los accionistas

BIMFR Medical EquipmentMercado FR
7D0.4%2.5%-0.3%
1Y0.08%27.9%-4.2%

Rentabilidad vs. Industria: Los resultados de BIM fueron inferiores a los de la industria French Medical Equipment, que obtuvo un rendimiento del 27.9% el año pasado.

Rentabilidad vs. Mercado: BIM superó al mercado French, que obtuvo un rendimiento del -4.2% el año pasado.

Volatilidad de los precios

Is BIM's price volatile compared to industry and market?
BIM volatility
BIM Average Weekly Movement3.1%
Medical Equipment Industry Average Movement5.5%
Market Average Movement4.5%
10% most volatile stocks in FR Market9.2%
10% least volatile stocks in FR Market2.2%

Precio estable de las acciones: BIM no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de BIM (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
196313,696Pierre Bouludwww.biomerieux.com

bioMérieux S.A. desarrolla y comercializa soluciones de diagnóstico in vitro para el diagnóstico de enfermedades infecciosas en América, Europa, Oriente Medio, África y Asia-Pacífico. La empresa ofrece CHROMID RANGE, un medio de cultivo cromógeno; RAPIDEC CARBA NP, una prueba bioquímica para la detección de bacterias productoras de carbapenemasas; sistemas de vigilancia del aire, la superficie y el agua; BACT/ALERT VIRTUO BACT/ALERT 3D, un sistema de cultivo de muestras de sangre; BIOFIRE, un sistema de reacción en cadena de la polimerasa (PCR) multiplex; BIOFIRE SPOTFIRE Lowplex PCR point-of-care; VITEK MS, un sistema de espectrometría de masas; VITEK 2, un sistema automatizado de identificación y pruebas de susceptibilidad antimicrobiana (AST); tiras de identificación normalizadas API RANGE; sistema rápido de AST VITEK REVEAL; método de gradiente ETEST en medios de cultivo; solución de secuenciación del genoma completo BIOMERIEUX EPISEQ CS para vigilancia epidemiológica; y VIDASB-R-A-H-M-S PCTTM, un marcador específico de infecciones bacterianas graves/sepsis. También ofrece Biomérieux vision suite, un software que proporciona información procesable para apoyar el diagnóstico y la toma de decisiones clínicas; medios de cultivo e instrumentos asociados; pruebas PCR ARGENE Monoplex; gamas NUCLISENS, un producto para la automatización del laboratorio de biología molecular y extracción; sistema EMAG Para la extracción de ADN y ARN; ESTREAM, una estación automatizada de preparación de muestras para procesar pruebas PCR; gamas GENE-UP y VERIFLOW para la detección de microorganismos para la industria alimentaria.

Resumen de fundamentos de bioMérieux S.A.

¿Cómo se comparan los beneficios e ingresos de bioMérieux con su capitalización de mercado?
Estadísticas fundamentales de BIM
Capitalización bursátil€11.65b
Beneficios(TTM)€411.30m
Ingresos (TTM)€3.81b

28.3x

Ratio precio-beneficio (PE)

3.1x

Ratio precio-ventas (PS)

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BIM
Ingresos€3.81b
Coste de los ingresos€1.69b
Beneficio bruto€2.12b
Otros gastos€1.71b
Beneficios€411.30m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)3.49
Margen bruto55.72%
Margen de beneficio neto10.81%
Ratio deuda/patrimonio10.1%

¿Cómo se ha desempeñado BIM a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

0.9%

Rentabilidad actual por dividendo

24%

Ratio de pagos